Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional acyclovir versus cryotherapy for extragenital cutaneous warts
IRCT20160523028008N37Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of aciclovir in verruca (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Complete clearance rate of extragenital cutaneous warts. Started Jan 2026; status: completed.
02
Drugs
aciclovir
03
Conditions
verruca
Beyond the preview
Go deeper on IRCT20160523028008N37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N37.